Method for stratifying a female subject for hormone replacement therapy

1) A method for stratifying a female subject for hormone replacement therapy comprising:

• determining the level of Pro-Neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject;
• and
• comparing said level of Pro-Neurotensin or fragments thereof with a pre-determined “pro-NT threshold” and
• wherein in case the determined level of Pro-Neurotensin or fragments thereof is above said pre-determined threshold then the subject is identified as having an enhanced risk to suffer an adverse event or having an enhanced risk to attract a disease in case of a hormone replacement therapy, and
• wherein in case the determined level of Pro-Neurotensin or fragments thereof is below said pre-determined threshold then the subject is identified as not having an enhanced risk to suffer an adverse event or as not having an enhanced risk to attract a disease in case of a hormone replacement therapy, and/or
• determining the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids (pENK) in a bodily fluid obtained from said female subject;
• and
• comparing said level of Pro-Enkephalin or fragments thereof with a pre-determined “pENK threshold” and
• wherein in case the determined level of Pro-Enkephalin or fragments thereof is below said pre-determined pENK threshold then the subject is identified as having an enhanced risk to suffer an adverse event or having an enhanced risk to attract a disease in case of a hormone replacement therapy, and
• wherein in case the determined level of Pro-Enkephalin or fragments thereof is above said pre-determined pENK threshold then the subject is identified as not having an enhanced risk to suffer an adverse event or as not having an enhanced risk to attract a disease in case of a hormone replacement therapy.